Drug Type Antisense oligonucleotides |
Synonyms GSK3389404 |
Target |
Mechanism Viral proteins inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis B, Chronic | Phase 2 | CN | 14 Feb 2017 | |
Hepatitis B, Chronic | Phase 2 | JP | 14 Feb 2017 | |
Hepatitis B, Chronic | Phase 2 | HK | 14 Feb 2017 | |
Hepatitis B, Chronic | Phase 2 | PH | 14 Feb 2017 | |
Hepatitis B, Chronic | Phase 2 | SG | 14 Feb 2017 | |
Hepatitis B, Chronic | Phase 2 | KR | 14 Feb 2017 | |
Hepatitis B, Chronic | Phase 2 | TH | 14 Feb 2017 | |
Hepatitis B, Chronic | Phase 2 | TH | 14 Feb 2017 | |
Hepatitis B | Phase 1 | GB | 17 Dec 2015 |
Phase 2 | 66 | vawhagjvjo(ogcwyqtvsh) = vuntdwvkll dgzxlbqmra (csqzuvspzc ) | - | 14 Jun 2022 | |||
Phase 2 | 78 | Placebo (Part 1: Placebo) | fshtbhaxgv(ttlkhrnmnd) = dxqwwbmedr btjemiwxcc (zzaitdpdtk, eeleahgazw - utnfvyaovl) View more | - | 22 Jan 2020 | ||
(Part 1: GSK3389404 30 mg) | fshtbhaxgv(ttlkhrnmnd) = oqvqutacsj btjemiwxcc (zzaitdpdtk, rzedqlqjej - xrmqvffkbg) View more | ||||||
Phase 1 | - | 42 | fqjlktarux(fzfppvjsma) = There were no serious adverse events (AEs) or withdrawals due to AEs fmjrfyqggr (jrtrlrpwoi ) View more | - | 01 Aug 2019 |